The purpose of this Cancer Center Support Grant is to reduce cancer incidence, morbidity and mortality by providing an organizational structure and administration which maximizes the quality and interdisciplinary nature of competitive funded cancer research activities at the City of Hope. The core grant provides the mechanisms for continuous planning and evaluation of the research programs of the Center in light of new research opportunities and a broad array of technical support via state-of-the-art shared facilities.
The specific aims are to: (1) stimulate collaborative research interactions between basic science and clinical investigators and among research groups in diverse areas of investigation; (2) facilitate and enhance interdisciplinary programs in basic and clinical research; (3) develop and support core research facilities to improve the effectiveness of the Center's research programs; (4) support the development of new investigators and new programs needed to maximize the contributions of the institution as a Cancer Center. The existence of an NCI-Designated Cancer Center at the City of Hope has enhanced the commitment to cancer research by the Board of Directors and senior scientific leadership of the City of Hope. The Board recently recruited a new director experienced in Cancer Center program development and administration and continues to provide exceptional financial support for renovation and construction of clinical and basic research facilities and support of research personnel. In turn, members of the Cancer Center have competed successfully for three program project grants (gene therapy; bone marrow transplantation for hematologic malignancies; and radioimmunotherapy of cancer), a drug discovery grant for the development and delivery of anti-viral RNA as treatments for AIDS; and two consortium grants for innovative, mechanistically oriented, Phase I and Phase II cancer therapeutic trials. Six outstanding young molecular biologists were recruited to expand the gene therapy program at a basic level. Two programs in the previous grant, Tumor and Cell Biology and Virology, have been eliminated and the outstanding components in each were merged into a new program in Molecular Carcinogenesis. The existing programs in Molecular Biology, Immunology, Hematology Malignancies and Clinical and Experimental Therapeutics have been enhanced. There are two new developing programs in Cancer Control and Prevention and Breast Cancer Research. Programs are supported by 12 cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA033572-19S4
Application #
6503332
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Ciolino, Henry P
Project Start
1981-07-01
Project End
2002-11-30
Budget Start
1999-08-01
Budget End
2002-11-30
Support Year
19
Fiscal Year
2001
Total Cost
$2,192,561
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137
Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590
Ding, Yuan Chun; Adamson, Aaron W; Steele, Linda et al. (2018) Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer 17:187-195
Kurata, Jessica S; Lin, Ren-Jang (2018) MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA 24:966-981
Hardwick, Nicola R; Frankel, Paul; Ruel, Christopher et al. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res 24:1315-1325
Dietze, Eric C; Chavez, Tanya A; Seewaldt, Victoria L (2018) Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol 188:280-290
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096

Showing the most recent 10 out of 1396 publications